ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
24.81
+1.38 (5.89%)
At close: Mar 9, 2026, 4:00 PM EDT
24.81
0.00 (0.00%)
After-hours: Mar 9, 2026, 4:10 PM EDT
ArriVent BioPharma Stock Forecast
Stock Price Forecast
The 10 analysts that cover ArriVent BioPharma stock have a consensus rating of "Strong Buy" and an average price target of $40.2, which forecasts a 62.03% increase in the stock price over the next year. The lowest target is $32 and the highest is $50.
Price Target: $40.2 (+62.03%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ArriVent BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 9 | 9 | 9 | 9 |
| Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 11 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Reiterates $44 → $50 | Buy | Reiterates | $44 → $50 | +101.53% | Mar 6, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $31 → $33 | Strong Buy | Maintains | $31 → $33 | +33.01% | Mar 6, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $42 → $44 | Strong Buy | Maintains | $42 → $44 | +77.35% | Mar 6, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Dec 23, 2025 |
| BTIG | BTIG | Strong Buy Initiates $45 | Strong Buy | Initiates | $45 | +81.38% | Dec 10, 2025 |
Financial Forecast
Revenue This Year
428.40K
Revenue Next Year
52.18M
from 428.40K
Increased by 12,079.97%
EPS This Year
-3.92
from -4.32
EPS Next Year
-2.89
from -3.92
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 4.4M | 137.7M | |||
| Avg | 428,400 | 52.2M | |||
| Low | n/a | 17.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 32,033.5% | |||
| Avg | - | 12,080.0% | |||
| Low | - | 3,896.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.90 | -2.45 | |||
| Avg | -3.92 | -2.89 | |||
| Low | -5.15 | -3.86 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.